Intellectual Property India Publishes Patent Application for 'A Formulation Comprising A Homogeneous Population Of Mesenchymal Stem Cells And Implementations Thereof' Filed by Regrow Biosciences Private Limited

MUMBAI, India, Oct. 24 -- Intellectual Property India has published a patent application (202421031909 A) filed by Regrow Biosciences Private Limited, Pune, Maharashtra, on April 22, 2024, for 'a formulation comprising a homogeneous population of mesenchymal stem cells and implementations thereof.'

Inventor(s) include Sanghavi, Satyen; and Kedage, Vinayak.

The application for the patent was published on Oct. 24, under issue no. 43/2025.

According to the abstract released by the Intellectual Property India: "The present disclosure relates to a formulation comprising: a) a population of mesenchymal stem cells (MSCs); and b) a carrier selected from serelaxin, Ringer's lactate solution, human serum albumin (HSA), dextran, heparin, hyaluronidase, or combinations thereof; wherein said population of MSCs is a homogeneous population having size in the range of 15-30 m; wherein at least 50% of the MSCs 10 express at least one marker selected from the group consisting of CD 90, CD73, and CD 105. The MSCs as part of the disclosed formulation exhibited 97% cell recovery and more than 90% cell viability."

Disclaimer: Curated by HT Syndication.